High levels of EphA3 expression are associated with high invasive capacity and poor overall survival in hepatocellular carcinoma

Oncology Reports

Volumn 30, Issue 5, 2013, Pages 2179-2186

  Lu, Cheng Yi ^a   Yang, Zhao Xu ^b   Zhou, Liang ^c   Huang, Zhi Zhong ^a   Zhang, Hong Tao ^b   Li, Jun ^b   Tao, Kai Shan ^b   Xie, Bai Zhi ^d  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^b FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^c The 155 Central Hospital of PLA   (China)

^d FOURTH MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Clinicopathological correlation; EphA3; Hepatocellular carcinoma; Invasion; Overall survival

Indexed keywords

EPHRIN RECEPTOR A3; SMALL INTERFERING RNA;

ADULT; ARTICLE; CANCER GRADING; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CELL MEMBRANE; CONTROLLED STUDY; CYTOPLASM; DOWN REGULATION; EPHA3 GENE; FEMALE; GENE EXPRESSION; GENE FUNCTION; GENE IDENTIFICATION; GENE LOCATION; GENETIC CORRELATION; GENETIC MARKER; HUMAN; HUMAN CELL; IN VITRO STUDY; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; METASTASIS; OVERALL SURVIVAL; PRIORITY JOURNAL; SURVIVAL TIME; TUMOR INVASION; TUMOR VOLUME; UPREGULATION;

AGED; CARCINOMA, HEPATOCELLULAR; DISEASE PROGRESSION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PROGNOSIS; RECEPTOR PROTEIN-TYROSINE KINASES; TUMOR MARKERS, BIOLOGICAL; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84885031693     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2013.2679     Document Type: Article

References (41)

1. Blume-Jensen P and Hunter T: Oncogenic kinase signalling. Nature 411: 355-365, 2001.
2. Klein R: Excitatory Eph receptors and adhesive ephrin ligands. Curr Opin Cell Biol 13: 196-203, 2001.
3. Noren NK and Pasquale EB: Eph receptor-ephrin bidirectional signals that target Ras and Rho proteins. Cell Signal 16: 655-666, 2004.
4. Wilkinson DG: Eph receptors and ephrins: regulators of guidance and assembly. Int Rev Cytol 196: 177-244, 2000.
5. Cooke JE and Moens CB: Boundary formation in the hindbrain: Eph only it were simple. Trends Neurosci 25: 260-267, 2002.
6. Krull CE, Lansford R, Gale NW, et al: Interactions of Eph-related receptors and ligands confer rostrocaudal pattern to trunk neural crest migration. Curr Biol 7: 571-580, 1997.
7. Gale NW, Holland SJ, Valenzuela DM, et al: Eph receptors and ligands comprise two major specificity subclasses and are reciprocally compartmentalized during embryogenesis. Neuron 17: 9-19, 1996.
8. Davy A and Robbins SM: Ephrin-A5 modulates cell adhesion and morphology in an integrin-dependent manner. EMBO J 19: 5396-5405, 2000.
9. Lawrenson ID, Wimmer-Kleikamp SH, Lock P, et al: Ephrin-A5 induces rounding, blebbing and de-adhesion of EphA3-expressing 293T and melanoma cells by CrkII and Rho-mediated signalling. J Cell Sci 115: 1059-1072, 2002.
10. Wang J, Dong Y, Wang X, et al: Expression of EphA1 in gastric carcinomas is associated with metastasis and survival. Oncol Rep 24: 1577-1584, 2010.
11. Nakamura R, Kataoka H, Sato N, et al: EPHA2/EFNA1 expression in human gastric cancer. Cancer Sci 96: 42-47, 2005.
12. Yuan W, Chen Z, Wu S, et al: Expression of EphA2 and E-cadherin in gastric cancer: correlated with tumor progression and lymphogenous metastasis. Pathol Oncol Res 15: 473-478, 2009.
13. Wang J, Li G, Ma H, et al: Differential expression of EphA7 receptor tyrosine kinase in gastric carcinoma. Hum Pathol 38: 1649-1656, 2007.
14. Hafner C, Schmitz G, Meyer S, et al: Differential gene expression of Eph receptors and ephrins in benign human tissues and cancers. Clin Chem 50: 490-499, 2004.
15. Wimmer-Kleikamp SH and Lackmann M: Eph-modulated cell morphology, adhesion and motility in carcinogenesis. IUBMB Life 57: 421-431, 2005.
16. Bae HJ, Song JH, Noh JH, et al: Low frequency mutation of the Ephrin receptor A3 gene in hepatocellular carcinoma. Neoplasma 56: 331-334, 2009.
17. Xi HQ and Zhao P: Clinicopathological significance and prognostic value of EphA3 and CD133 expression in colorectal carcinoma. J Clin Pathol 64: 498-503, 2011.
18. Chu D, Li Y, Wang W, et al: High level of Notch1 protein is associated with poor overall survival in colorectal cancer. Ann Surg Oncol 17: 1337-1342, 2010.
19. Zhou L, Wang DS, Li QJ, Sun W, Zhang Y and Dou KF: Downregulation of the Notch signaling pathway inhibits hepatocellular carcinoma cell invasion by inactivation of matrix metalloproteinase-2 and -9 and vascular endothelial growth factor. Oncol Rep 28: 874-882, 2012.
20. Raspollini MR, Amunni G, Villanucci A, Baroni G, Boddi V and Taddei GL: Prognostic significance of microvessel density and vascular endothelial growth factor expression in advanced ovarian serous carcinoma. Int J Gynecol Cancer 14: 815-823, 2004.
21. Dodelet VC and Pasquale EB: Eph receptors and ephrin ligands: embryogenesis to tumorigenesis. Oncogene 19: 5614-5619, 2000.
22. Clevers H and Batlle E: EphB/EphrinB receptors and Wnt signaling in colorectal cancer. Cancer Res 66: 2-5, 2006.
23. Nakamoto M and Bergemann AD: Diverse roles for the Eph family of receptor tyrosine kinases in carcinogenesis. Microsc Res Tech 59: 58-67, 2002.
24. Brantley-Sieders D, Schmidt S, Parker M and Chen J: Eph receptor tyrosine kinases in tumor and tumor microenvironment. Curr Pharm Des 10: 3431-3442, 2004.
25. Héroult M, Schaffner F and Augustin HG: Eph receptor and ephrin ligand-mediated interactions during angiogenesis and tumor progression. Exp Cell Res 312: 642-650, 2006.
26. Xi HQ, Wu XS, Wei B and Chen L: Aberrant expression of EphA3 in gastric carcinoma: correlation with tumor angiogenesis and survival. J Gastroenterol 47: 785-794, 2012.
27. Davies H, Hunter C, Smith R, et al: Somatic mutations of the protein kinase gene family in human lung cancer. Cancer Res 65: 7591-7595, 2005.
28. Bardelli A, Parsons DW, Silliman N, et al: Mutational analysis of the tyrosine kinome in colorectal cancers. Science 300: 949, 2003.
29. Bonifaci N, Gorski B, Masojc B, et al: Exploring the link between germline and somatic genetic alterations in breast carcinogenesis. PLoS One 5: e14078, 2010.
30. Lee JS and Thorgeirsson SS: Comparative and integrative functional genomics of HCC. Oncogene 25: 3801-3809, 2006.
31. Boyd AW, Ward LD, Wicks IP, et al: Isolation and characterization of a novel receptor-type protein tyrosine kinase (hek) from a human pre-B cell line. J Biol Chem 267: 3262-3267, 1992.
32. Wicks IP, Wilkinson D, Salvaris E and Boyd AW: Molecular cloning of HEK, the gene encoding a receptor tyrosine kinase expressed by human lymphoid tumor cell lines. Proc Natl Acad Sci USA 89: 1611-1615, 1992.
33. Dottori M, Down M, Hüttmann A, Fitzpatrick DR and Boyd AW: Cloning and characterization of EphA3 (Hek) gene promoter: DNA methylation regulates expression in hematopoietic tumor cells. Blood 94: 2477-2486, 1999.
34. Fox BP, Tabone CJ and Kandpal RP: Potential clinical relevance of Eph receptors and ephrin ligands expressed in prostate carcinoma cell lines. Biochem Biophys Res Commun 342: 1263-1272, 2006.
35. Fidler IJ: The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis revisited. Nat Rev Cancer 3: 453-458, 2003.
36. Weiss L: Metastasis of cancer: a conceptual history from antiquity to the 1990s. Cancer Metastasis Rev 19: I-XI, 193-383, 2000.
37. Wey JS, Fan F, Gray MJ, et al: Vascular endothelial growth factor receptor-1 promotes migration and invasion in pancreatic carcinoma cell lines. Cancer 104: 427-438, 2005.
38. Takahashi Y, Kitadai Y, Bucana CD, Cleary KR and Ellis LM: Expression of vascular endothelial growth factor and its receptor, KDR, correlates with vascularity, metastasis, and proliferation of human colon cancer. Cancer Res 55: 3964-3968, 1995.
39. Folkman J: What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 82: 4-6, 1990.
40. Joo YE, Sohn YH, Lee WS, et al: Expression of vascular endothelial growth factor and p53 in pancreatic carcinomas. Korean J Intern Med 17: 153-159, 2002.
41. Zeng H, Datta K, Neid M, Li J, Parangi S and Mukhopadhyay D: Requirement of different signaling pathways mediated by insulin-like growth factor-I receptor for proliferation, invasion, and VPF/VEGF expression in a pancreatic carcinoma cell line. Biochem Biophys Res Commun 302: 46-55, 2003.